Ulcerative Colitis (UC)
Pipeline by Development Stage
Drug Modality Breakdown
Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.
Key Trends
- JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
- Multiple patent cliffs emerging 2026-2028, creating generic competition risk
- Robust pipeline with 4,996 trials signals continued innovation and market expansion
Career Verdict
Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (TIRZEPATIDE) | Eli Lilly and Company | $2.4B | 16% | PEAK | Growing | 15.7yr |
| 2 | SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) | AstraZeneca | $2.0B | 13% | LOE_APPROACHING | Stable | |
| 3 | JAKAFI (RUXOLITINIB) | Incyte | $1.9B | 13% | LOE_APPROACHING | Declining | 2.6yr |
| 4 | RESTASIS (CYCLOSPORINE) | AbbVie | $1.5B | 10% | PEAK | Stable | 8.0yr |
| 5 | RINVOQ (UPADACITINIB) | AbbVie | $976M | 7% | PEAK | Growing | 11.8yr |
Drug Class Breakdown
dominant class with patent cliff risk
established, mature market segment
driven by single blockbuster
established immunosuppression class
legacy biologic class with competition
Career Outlook
GrowingImmunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.
Breaking In
Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.
For Experienced Professionals
Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.
In-Demand Skills
Best For
Hiring Landscape
Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.
Top Hiring Companies
By Department
Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.
On Market (1)
Approved therapies currently available
Competitive Landscape
14 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 16 trials with date data
Clinical Trials (16)
Total enrollment: 4,834 patients across 16 trials
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
Efficacy & Safety of TD-1473 in Ulcerative Colitis
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
Related Jobs in Immunology
Director, Bioanalytical / Biomarkers
Senior Director, Regulatory Affairs Strategy
Associate Director, Pharmacovigilance
Regional Business Director, (West Region), Immunology
Regional Business Director, (Southeast Region), Immunology
Regional Business Director, (South Central Region), Immunology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.